Australia Influenza Vaccine Market Size & Outlook, 2024-2030
- Pharmaceuticals
- Vaccines
- Influenza Vaccine Market Outlook
- Vaccines
Global Market
Related Markets
Ask a question about the influenza vaccine market
Australia influenza vaccine market highlights
- The Australia influenza vaccine market generated a revenue of USD 106.4 million in 2023 and is expected to reach USD 179.5 million by 2030.
- The Australia market is expected to grow at a CAGR of 7.9% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 106.4 million |
| Market revenue in 2030 | USD 179.5 million |
| Growth rate | 7.9% (CAGR from 2024 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, Australia accounted for 1.3% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 477.8 million by 2030.
Supportive government initiatives are the key driving factor for the Australia influenza vaccine market. For instance, in June 2022, the Australian Government launched a USD 11 million ad campaign to encourage the uptake of flu vaccines and COVID-19 boosters. The government undertook this initiative to promote vaccination in the country and reduce the burden of influenza.
The favorable regulatory framework and high demand for influenza vaccines in the country are likely to boost market expansion. For instance, in March 2022, Seqirus announced that its Flucel vax Quad (quadrivalent influenza vaccine) was approved by the Therapeutic Goods Administration (TGA) for children aged 2 years and older.
No credit card required*
Publish Date: Dec 15, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Viatris Inc | View profile | 38,000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | www.viatris.com |
| Sinovac Biotech Ltd | View profile | 3,261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | www.sinovac.com |
| CSL Ltd | View profile | 32,000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | www.csl.com |
| Emergent BioSolutions Inc | View profile | 1,600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | www.emergentbiosolutions.com |
| Vaxess Technologies | View profile | 51-100 | Cambridge, Massachusetts, United States, North America | www.vaxess.com |
| Osivax | View profile | 11-50 | Lyon, Rhone-Alpes, France, Europe | www.osivax.com/ |
Australia Influenza Vaccine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Influenza Vaccine Market Outlook will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 97.74% in 2023.
Horizon Databook has segmented the Australia influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
Supportive government initiatives are the key driving factor for the Australia influenza vaccine market. For instance, in June 2022, the Australian Government launched a USD 11 million ad campaign to encourage the uptake of flu vaccines and COVID-19 boosters. The government undertook this initiative to promote vaccination in the country and reduce the burden of influenza.
The favorable regulatory framework and high demand for influenza vaccines in the country are likely to boost market expansion. For instance, in March 2022, Seqirus announced that its Flucel vax Quad (quadrivalent influenza vaccine) was approved by the Therapeutic Goods Administration (TGA) for children aged 2 years and older.
- Australia Influenza Vaccine Market Vaccine Type Outlook (Revenue, USD Million , 2018-2030)
- Inactivated
- Live Attenuated
- Australia Influenza Vaccine Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Quadrivalent
- Trivalent
- Australia Influenza Vaccine Market Age Group Outlook (Revenue, USD Million , 2018-2030)
- Pediatric
- Adult
- Australia Influenza Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2018-2030)
- Injection
- Nasal Spray
- Australia Influenza Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Pharmacy
- Government & Institutional supply
- Other Distribution Channels
Reasons to subscribe to Influenza Vaccine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Influenza Vaccine Market Outlook databook
- Our clientele includes a mix of Influenza Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Influenza Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Influenza Vaccine Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Australia Influenza Vaccine Market, 2018-2030 (US$M)
Australia influenza vaccine market statistics, by vaccine type, 2018-2030 (US$M)
